VectivBio Holding AG (VECT)

NASDAQ
6.50
+0.07(+1.09%)
After Hours
6.31
-0.19(-2.92%)
- Real-time Data
  • Volume:
    25,945
  • Day's Range:
    6.15 - 6.64
  • 52 wk Range:
    2.74 - 6.99

VECT Overview

Prev. Close
6.43
Day's Range
6.15-6.64
Revenue
-
Open
6.64
52 wk Range
2.74-6.99
EPS
-2.39
Volume
25,945
Market Cap
293.58M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
15,838
P/E Ratio
-
Beta
-
1-Year Change
-2.99%
Shares Outstanding
45,166,599
Next Earnings Date
Nov 30, 2022
What is your sentiment on VectivBio Holding AG?
or
Market is currently closed. Voting is open during market hours.

VectivBio Holding AG Company Profile

VectivBio Holding AG Company Profile

Employees
0

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

Read More

Analyst Price Target

Average21.20 (+226.15% Upside)
High28
Low14
Price6.5
No. of Analysts5
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyStrong BuyStrong BuyBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy